Atlas of mpox lesions: a tool for clinical researchers, version 1.0, 28 April 2023

WHO/MPX/Clinical/Lesions/2023.1

© World Health Organization 2023

All rights reserved.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The Atlas of mpox lesions: a tool for clinical researchers is intended for use by the international clinical trialists to aid the uniformity of data collection and clinical evidence which will inform the global effort to inform clinical severity characterization of mpox disease.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in France
Contents

Acknowledgements ................................................................. iv
Abbreviations ........................................................................ vi

Background ............................................................................. 1
  Introduction ........................................................................... 1
  Rationale .............................................................................. 1
  Collation of the images ........................................................... 1
  Classification of the images ...................................................... 1
  Presentation of the images ....................................................... 1
  Future plans .......................................................................... 1

1. Active lesions ....................................................................... 2
  Active cutaneous .................................................................... 2
  Active mucosal ....................................................................... 2
  Main images (active lesions) .................................................... 2
  Extra images (genital/mucosal – active lesions) ......................... 4
  Extra images (non-genital – active lesions) ............................... 6

2. Crusted and scabbed lesions .................................................... 8
  Main images (crusted and scabbed lesions) ............................... 8

3. Resolved and healed lesions ................................................... 9
  Main images (resolved and healed lesions) ............................... 9

4. Other clinical findings ........................................................... 11

Annex. Conflicts declared in Declaration of Interests forms ............... 13
Acknowledgements

The World Health Organization (WHO) would like to thank the following contributors: Edward Cowen (Dermatology Consultation Service, National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States of America); Vanessa Cramond (Health Emergencies Programme [WHE], WHO headquarters); Janet Diaz (WHE, WHO headquarters); Kieron Leslie (University of California, San Francisco, United States of America); Jamie Rylance (WHE, WHO headquarters); Julie Viry (WHE, WHO headquarters).

Medical photography contributors:
Bichat Claude Bernard Hospital, APHP (France); Evandro Chagas National Institute of Infectious Diseases Fiocruz, (Brazil); Fundación Lucha contra las Infecciones (Spain); Hospital Clinic de Barcelona (Spain); Irrua Specialist Teaching Hospital (Nigeria); Lagos State University Teaching Hospital (Nigeria); University of Toronto, (Canada); Zuckerberg San Francisco General Hospital (United States of America).

Atlas of mpox lesions Working Group (11 October 2022):
Co-chairs: Edward Cowen (Dermatology Consultation Service, National Institute of Arthritis and Musculoskeletal and Skin Diseases, United States of America); Kieron Leslie (University of California, San Francisco, United States of America).

Oluwatoyin Akinsiku (Lagos Federal Medical Center, Nigeria); Chloe Bertin (Bichat Claude Bernard Hospital; APHP, France); Jose Luis Blanco (Infectious Diseases– Sexual Health Programme, Hospital Clinic de Barcelona, Spain); Matthias Bonk (WHE, WHO Regional Office for Europe); Alba Catala (Dermatology – Sexual Health Programme, Hospital Clinic de Barcelona, Spain); Adrienne Chan (Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Canada); Olufolakemi Cole-Adeife (Lagos State University Teaching Hospital, Nigeria); Candida Fernandes (Serviço de Dermatovenereologia, Centro Hospitalar Universitário de Lisboa Central, Portugal); Esther Freeman (Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, United States of America); Irene Fuertes (Dermatology and Venereology – Sexual Health Programme, Hospital Clinic de Barcelona, Spain); Cristina Galvan, (Fundación Lucha contra las Infecciones and University Hospital of Móstoles, Madrid Spain, DerMalawi project, Malawi); Sami Gottlieb (Department of Sexual and Reproductive Health and Research, WHO headquarters); Beatriz Grinsztejn (STI/HIV Clinical Research Laboratory, Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Brazil); Elizabeth Higgs (National Institute of Health, Unites States of America); Rashidatu Kamara (WHE, WHO Regional Office for Africa); Van Kawaya (Ministry of Health, Democratic Republic of the Congo); Emerencienne Kibangou (WHE, WHO Regional Office for Africa); Chiori Kodama (WHE WHO Regional Office for the Eastern Mediterranean); Rosamond Lewis (WHE, WHO headquarters); Placide Mbala (Institut National de Recherche Biomedicale, DRC); Antons Mozalevskis (HIV/Sexually Transmitted Infections, WHO headquarters); Emmanuel Nakoune (Institut Pasteur de Bangui, Central African Republic); Sebastine Oiwoh (Dermatology and Venereology Unit, Department of Medicine, Irrua Specialist Teaching Hospital, Nigeria); Tochi Okwor (Centre for Disease Control, Nigeria); Nathan Peiffer-Smadja (Bichat Claude Bernard Hospital; APHP, France); Dina Pfeifer (WHE WHO Regional Office for Europe); Josep Riera- Monroig (Dermatology – Sexual Health Programme, Hospital Clinic de Barcelona, Spain); Amanda Rojek (Pandemic Sciences Institute, University of Oxford, United Kingdom of Great Britain and Northern Ireland and Royal Melbourne Hospital, Australia); Inga Saknitr (Vanderbilt University Medical Center, United States of America); Mayara Secco (STI/ HIV Clinical Research Laboratory, Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Brazil); Ollivier Segeral (HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Switzerland); Nathalie Strub-Wourgaft (Drugs for Neglected Diseases initiative, Switzerland); Sharon Sukhdeo (University of Toronto, Canada); Eric Tkaczyk (Vanderbilt University Medical Center, United States of America); Laurence
Toutous Trellu (Dermatology and Veneraology division, University Hospital of Geneva, Switzerland); Teodora Wi (Sexually Transmitted Infection, Global HIV, Hepatitis and STIs Programme, WHO headquarters); Yazdan Yazdanpanah (Bichat Claude Bernard Hospital; APHP, Inserm/ANRS, Paris Cité University, France); Adesola Yinka-Ogunleye (WHE, WHO headquarters); Jason Zucker (Columbia University Vagelos College of Physicians and Surgeons, United States of America).

Funded by WHO.
Abbreviations

WHE  Health Emergencies Programme (WHO)
WHO  World Health Organization
**Background**

**Introduction**
Global understanding of the natural history of monkeypox (now recognised as mpox), its clinical features, risk factors for severe disease and outcomes remains incomplete, and the multicountry outbreak identified in May 2022 (caused by clade 2 virus) has affected new populations across new geographical areas of the world.

In July 2022, WHO convened a working group of international clinical trialists and clinical experts in an effort to improve characterization and assessment of mpox skin lesions. Three preliminary meetings took place (18 and 25 August and 8 September 2022). The outcome of these meetings is the *Atlas of mpox lesions*, which aims to aid the uniformity of data collection and clinical evidence generation by researchers to further inform the characterization of mpox disease.

**Rationale**
The *Atlas of mpox lesions* underpins a common understanding of the stages of disease, including the appearances of both archetypal mpox lesions, and those with less typical features.

The *Atlas of mpox lesions* will be revised as more medical photography becomes available and/or should further characterization of lesions evolve.

**Collation of the images**
The images have been collated from global experts (see medical photography contributor list in the acknowledgements). These images have been collected as part of routine care or clinical trials with full informed consent for medical photography and use of images for teaching, educational and medical publication purposes.

Rights of the medical photography remains with the contributing institutions and they should be contacted directly for attribution or reuse. For contact details write to CMTM@WHO.int

**Classification of the images**
An expert group classified each available image into categories of:
1. Active lesions.
2. Crusted and scabbed lesions.
3. Resolved and healed lesions.

**Presentation of the images**
For each lesion category group, between 3 and 5 archetypal images are highlighted. Additional extra images aim to display the variation of appearance between individuals, skin colours and sites of lesion.

**Future plans**
This first version of the atlas is intended to be a basis for future expansion. Specifically, as images become more available, we expect to include more representing severe disease, and lesions affecting skin of colour.
1. Active lesions

Active cutaneous
The active category of lesions includes most of the variable morphologies described of cutaneous MPX.

| Early lesions | Typically 1–3 mm that appear solid, are known as papules. Other lesions may develop a clear fluid-filled appearance known as a vesicle or, more often, will appear to contain white material (pustule/pseudo-pustule). |
| Progression   | As lesions progress, central involution of the lesion may lead to a torus (doughnut) shape (umbilicated pseudo-pustule). A scale crust often develops first in the umbilicated central area of evolving skin lesions. |
| Late stage    | Erosions and ulcers may also occur, which are also considered active. Superficial loss of a portion of the epidermis is an erosion, whereas full-thickness loss of the entire epidermis is an ulcer. |

Active mucosal
There are three morphologies typically seen in the mouth: ulcerations/erosions without surrounding induration; papules and nodules resembling chancres; and pseudomembranous (sloughy) plaques mimicking candidiasis. All these lesions heal quickly without crust formation or dyspigmentation.

Main images (active lesions)

Fig. 1. Umbilicated pseudopustules (doughnut-shaped) lesions
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 2. Genital pseudopustules
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)
Fig. 3. Umbilicated pseudopustules (doughnut-shaped) lesions
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 4. Pseudopustules on arm mimicking target lesions
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 5. Ulcer with purulent base
Source: Zuckerberg San Francisco General Hospital (USA)
Extra images (genital /mucosal – active lesions)

Fig. 6.  
*Source:* Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 7.  
*Source:* Hospital Clínic de Barcelona (Spain)

Fig. 8.  
*Source:* Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 9.  
*Source:* Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 10.  
*Source:* Hospital Clínic de Barcelona (Spain)

Fig. 11.  
*Source:* Hospital Clínic de Barcelona (Spain)
1. Active lesions

Fig. 12.  
Source: Hospital Clínic de Barcelona (Spain)

Fig. 13.  
Source: Hospital Clínic de Barcelona (Spain)

Fig. 14.  
Source: Hospital Clínic de Barcelona (Spain)

Fig. 15.  
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)
Extra images (non-genital – active lesions)

Fig. 16.  
Source: Hospital Clinic de Barcelona (Spain)

Fig. 17.  
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 18.  
Source: Hospital Clinic de Barcelona (Spain)

Fig. 19.  
Source: Hospital Clinic de Barcelona (Spain)

Fig. 20.  
Source: University of Toronto (Canada)

Fig. 21.  
Source: University of Toronto (Canada)
1. Active lesions

Fig. 22.  
Source: Hospital Clinic de Barcelona (Spain)

Fig. 23.  
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 24.  
Source: Lagos State University Teaching Hospital (Nigeria)

Fig. 25.  
Source: Fundación Lucha contra las Infecciones (Spain)

Fig. 26.  
Source: Fundación Lucha contra las Infecciones (Spain)
2. Crusted and scabbed lesions

Evolving lesions may develop a surface of thick surface scale (stratum corneum), yellow serous crust, haemorrhagic crust or scab (eschar). Crusted lesions are considered infectious until the underlying lesion has completely resolved and the surface crust has been replaced by a full layer of epidermis. At this stage, most of the lesion should have crust without surrounding skin thickening (induration).

Main images (crusted and scabbed lesions)

Fig. 27. Crust on upper lip
Source: University of Toronto (Canada)

Fig. 28. Crust on scalp
Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)

Fig. 29. Eschar on penis
Source: Irrua Specialist Teaching Hospital (Nigeria)
3. Resolved and healed lesions

Lesions are considered resolved once the lesion is no longer raised above the skin, any residual crust has resolved (desquamation) and any underlying erosion or ulcer has healed with intact skin (re-epithelialization).

Main images (resolved and healed lesions)

![Post-inflammatory changes with pink scars](source)

Fig. 30. Post-inflammatory changes with pink scars  
*Source: Fundación Lucha contra las Infecciones (Spain)*

![Depressed scar](source)

Fig. 31. Depressed scar  
*Source: Evandro Chagas National Institute of Infectious Diseases-Fiocruz (Brazil)*

![Re-epithelialized lesion with surrounding collarate of scale](source)

Fig. 32. Re-epithelialized lesion with surrounding collarate of scale  
*Source: Zuckerberg San Francisco General Hospital (USA)*

![Faint post-inflammatory pigmentation](source)

Fig. 33. Faint post-inflammatory pigmentation  
*Source: Zuckerberg San Francisco General Hospital (USA)*
Fig. 34. Pink scarring at base of penis
Source: Zuckerberg San Francisco General Hospital (USA)

Fig. 35. Multiple scars with hypo- and hyper-pigmentation
Source: Fundación Lucha contra las Infecciones (Spain)
4. Other clinical findings

Additional clinical manifestations include a skin exanthem and ocular involvement.

Fig. 36.  
*Source: Bichat Claude Bernard Hospital, APHP (France)*

Fig. 37  
*Source: Bichat Claude Bernard Hospital, APHP (France)*

Fig. 38.  
*Source: Bichat Claude Bernard Hospital, APHP (France)*

Fig. 39  
*Source: Bichat Claude Bernard Hospital, APHP (France)*
Fig. 40
Source: Bichat Claude Bernard Hospital, APHP (France)
Annex. Conflicts declared in Declaration of Interests forms

All contributors to the mpox atlas have completed declaration of interest statements. These have been reviewed by WHO Secretariat, as below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Conflicts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oluwatoyin Akinsiku</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Chloe Bertin</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Jose Luis Blanco</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Alba Catala</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Adrienne Chan</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Olufolakemi Cole-Adeife</td>
<td>I was a member of the Emergency Operation Command (EOC) for Mpox surveillance and Case management in Lagos State during the 2022 Mpox Outbreak from July to October 2022. This EOC was coordinated the Lagos State Ministry of Health and supported by WHO Nigeria. I was appointed as a medical expert, a physician and dermatologist working for Lagos State. I am also involved in the writing of academic publications (case reports and case series) on some of the Mpox cases managed in Lagos State during the 2022 outbreak. These publications are not funded by any person or organisation. Decision: no action needed.</td>
</tr>
<tr>
<td>Edward Cowen</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Candida Fernandes</td>
<td>I currently run the STD clinic of the Dermato venereology Department at Centro Hospitalar e Universitario de Lisboa Central (2400 euros/month). Decision: no action needed.</td>
</tr>
<tr>
<td>Esther Freeman</td>
<td>I am the principal investigator of the Dermatology COVID-19, monkeypox and emerging infections registry, which is a collaboration between the American Academy of Dermatology, the International League of Dermatologic Societies, and the Massachusetts General Hospital. From 2020-2022, Massachusetts General Hospital received research grants from the ILDS to support the registry. I also hold an (unpaid) position as an external advisor to the International League of Dermatologic Societies (2020 to present). I also hold an (unpaid) position on the American Academy of Dermatology Ad Hoc Task Force on Monkeypox (2022 to present). Decision: no action needed.</td>
</tr>
<tr>
<td>Irene Fuertes</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Cristina Galvan</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Beatriz Grinsztejn</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Elizabeth Higgs</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Van Kawaya</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Placide Mbala</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Kieron Leslie</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Placide Mbala</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Emmanuel Nakoune</td>
<td>I have a DOI from him relating to Mpox (guideline) – no conflict declared.</td>
</tr>
<tr>
<td>Sebastine Oiwoh</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Tochi Okwor</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Nathan Peiffer</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Josep Riera-Monroig</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Amanda Rojek</td>
<td>The Pandemic Sciences Institute, and ISARIC, which I have affiliations with, receive funding to conduct clinical research in epidemic diseases, including monkeypox. Decision: no action needed.</td>
</tr>
<tr>
<td>Name</td>
<td>Conflicts</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Inga Saknite</td>
<td>Since 2022, I am the owner and board member of a limited liability company “Skin Imaging Consulting” based in Latvia. The company is a subcontractor for VUMC on a VUMC/Leidos contract to provide support for the PALM007 mpx study in the Democratic Republic of the Congo ($60,000). Specifically, I provide study support including photo documentation (developing photography guidelines and providing photography training), and source document development on lesion counting in the field. Decision: no action needed.</td>
</tr>
<tr>
<td>Mayara Secco</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Olivier Segeral</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Nathalie Strub-Wourgaft</td>
<td>PANTHER – the outcome of this meeting will inform/support the definition of endpoint sued in the clinical trial the PANTHER (that I am representing here) will use and how the data will later be interpreted. Decision: no action needed.</td>
</tr>
<tr>
<td>Sharon Sukhdeo</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Eric Tkaczyk</td>
<td>I have received salary, through VUMC, to develop monkeypox AI and support the PALM007 trial via a research contract from the NIH. Decision: no action needed.</td>
</tr>
<tr>
<td>Laurence Toutous Tréllu</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Sharon Walmsley</td>
<td>Research grant for RCT of tecovirimat for Mpxo, PHAC: $500,00 (2022). Decision: no action needed.</td>
</tr>
<tr>
<td>Yaszdan Yazdanpanah</td>
<td>No conflict declared.</td>
</tr>
<tr>
<td>Jason Zucker</td>
<td>No conflict declared.</td>
</tr>
</tbody>
</table>